Clinical trial
Phase II Study of Atorvastatin, Micro-dose Methotrexate and Tacrolimus Administered Only to Transplant Recipients for the Prophylaxis of Acute Graft-versus-host Disease Following Allogeneic Hematopoietic Cell Transplantation
NCT01665677 is registered in ClinicalTrials.gov with Mehdi Hamadani as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Atorvastatin, Micro-dose Methotrexate and Tacrolimus Administered Only to Transplant Recipients for the Prophylaxis of Acute Graft-versus-host Disease Following Allogeneic Hematopoietic Cell Transplantation
- Lead sponsor
- Mehdi Hamadani
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 20, 2014
- Completion date
- July 9, 2021
- Enrollment
- 69 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.